Literature DB >> 28717895

Correlating uptake and activity of proline-rich antimicrobial peptides in Escherichia coli.

Luzia Holfeld1,2, Ralf Hoffmann3,4, Daniel Knappe3,4.   

Abstract

Increasing death tolls accounted for by antimicrobial drug resistance demand novel antibiotic lead compounds. Among different promising candidate classes, proline-rich antimicrobial peptides (PrAMPs) are very favorable due to their intracellular mechanism, i.e., binding to the 70S ribosome and DnaK, after active uptake relying on bacterial transporters like SbmA and MdtM. Studies on peptide internalization as the first step of their complex mode of action rely typically on fluorophore or radioactive labeling and quantification using microscopy, flow cytometry, or radioactivity. Here, a liquid chromatography based assay was applied to quantify the unlabeled internalized full-length peptides and their proteolytic degradation products (metabolites) using UV absorbance and mass spectrometry. Knockout mutants lacking transporter proteins showed reduced PrAMP uptakes, explaining their reduced susceptibility against PrAMPs. Interestingly, major metabolites produced by bacterial proteases still bound to the 70S ribosome provide evidence that degradation by cytosolic proteases as a possible resistance mechanism is not very efficient. Graphical abstract The uptake of unlabeled proline-rich antimicrobial peptides (PrAMPs) is analyzed in Escherichia coli BW25113 wild-type and transporter knockout mutants ΔsbmA and BS2 (ΔsbmA yjiL::Tn10) by reversed-phase chromatography and quantified by UV detection or mass spectrometry with multi-reaction monitoring (scheme right). Internalized peptide amounts correlated to minimal inhibitory concentrations and bacterial transport activities based on the present transporter proteins (scheme left).

Entities:  

Keywords:  Apidaecin; Label-free quantification; Mass spectrometry; Oncocin; Proline-rich antimicrobial peptide (PrAMP); Reversed-phase chromatography

Mesh:

Substances:

Year:  2017        PMID: 28717895     DOI: 10.1007/s00216-017-0496-2

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  6 in total

1.  Short Proline-Rich Lipopeptide Potentiates Minocycline and Rifampin against Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa.

Authors:  Ronald Domalaon; Yaroslav Sanchak; Linet Cherono Koskei; Yinfeng Lyu; George G Zhanel; Gilbert Arthur; Frank Schweizer
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

2.  Antimicrobial Activity and 70S Ribosome Binding of Apidaecin-Derived Api805 with Increased Bacterial Uptake Rate.

Authors:  Tobias Ludwig; Andor Krizsan; Gubran Khalil Mohammed; Ralf Hoffmann
Journal:  Antibiotics (Basel)       Date:  2022-03-23

3.  Effect of Amino Acid Substitutions on 70S Ribosomal Binding, Cellular Uptake, and Antimicrobial Activity of Oncocin Onc112.

Authors:  Lisa Kolano; Daniel Knappe; Angela Berg; Thorsten Berg; Ralf Hoffmann
Journal:  Chembiochem       Date:  2022-01-12       Impact factor: 3.461

4.  Advantage of a Narrow Spectrum Host Defense (Antimicrobial) Peptide Over a Broad Spectrum Analog in Preclinical Drug Development.

Authors:  Eszter Ostorhazi; Ralf Hoffmann; Nicole Herth; John D Wade; Carl N Kraus; Laszlo Otvos
Journal:  Front Chem       Date:  2018-08-21       Impact factor: 5.221

5.  Ribosomal Target-Binding Sites of Antimicrobial Peptides Api137 and Onc112 Are Conserved among Pathogens Indicating New Lead Structures To Develop Novel Broad-Spectrum Antibiotics.

Authors:  Lisa Kolano; Daniel Knappe; Daniela Volke; Norbert Sträter; Ralf Hoffmann
Journal:  Chembiochem       Date:  2020-06-30       Impact factor: 3.164

6.  Influence of Substitutions in the Binding Motif of Proline-Rich Antimicrobial Peptide ARV-1502 on 70S Ribosome Binding and Antimicrobial Activity.

Authors:  Alexandra Brakel; Andor Krizsan; Renke Itzenga; Carl N Kraus; Laszlo Otvos; Ralf Hoffmann
Journal:  Int J Mol Sci       Date:  2022-03-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.